Latest Intelligence on Central Nervous System in Asia-Pacific

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Lundbeck: Japanese expansion to lift the mood ahead of expiries

Lundbeck's commercial partners Mochida and Mitsubishi Tanabe have launched its antidepressant Lexapro in Japan. The Japanese antidepressant market is attractive, with relatively few marketed brands and a large prevalent population. However, Datamonitor expects that Mochida and Mitsubishi Tanabe will be unable to emulate the drug's success in the US market.

Published By Datamonitor
22 Aug 2011
CommentWire
CommentWire

Lundbeck: limited last-line US positioning awaits Serdolect

The FDA-appointed Psychopharmacology Drug Advisory Committee has voted against the use of Lundbeck's Serdolect in a broad schizophrenia population due to safety concerns, recommending approval for the treatment of refractory patients only. With disappointing sales in Europe following the drug's 2005 relaunch, the return on investment for Lundbeck to enter the US with Serdolect is unclear.

Published By Datamonitor
08 Apr 2009
ResearchWire
ResearchWire

Major depressive disorder: growth markets

Published By Datamonitor
26 Sep 2007
ResearchWire
ResearchWire

Major Depressive Disorder: key market prevalences

Published By Datamonitor
26 Feb 2002
ResearchWire
ResearchWire

Major depressive disorder: potential high sales for GSK's pipeline drug

Published By Datamonitor
02 Apr 2007
CommentWire
CommentWire

Medivation: Dimebon ever closer to Alzheimer's market

Medivation is set to announce trial data regarding behavioral symptoms and the impact on caregivers relating to its Alzheimer's disease drug, Dimebon. Positive findings will enhance the validity of the impressive Phase II clinical trial data published in 2007. Dimebon is forecast for a 2011 launch, and is expected to account for 15% ($1.5 billion) of the $9.5 billion AD market by 2017.

Published By Datamonitor
14 Mar 2008
CommentWire
CommentWire

Merck Serono: cladribine's failure is a big setback for the company, not MS patients

Swiss drugmaker Merck Serono has announced the discontinuation of additional trials for cladribine and the withdrawal of the product from the Russian and Australian markets, showing that the firm has decided to cut its losses and accept a costly failure. The decision to discontinue a once potentially blockbusting therapy is a huge setback for Merck and its multiple sclerosis portfolio.

Published By Datamonitor
22 Jun 2011
Expert View
Expert View

Merck: suvorexant on track to refresh insomnia market

Merck & Co. has announced positive Phase III data for its insomnia candidate suvorexant, renewing hope in the novel orexin receptor antagonist drug class after speculation about class-wide safety issues. Although suvorexant has the potential to address key unmet needs in the treatment of insomnia, demonstration of superiority over zolpidem and lack of scheduling will be key to commercial success.

Published By Datamonitor
12 Sep 2012
Expert View
Expert View

Migraine market: Trexima approval delays benefits generic triptan

Estimated to be worth $3.4 billion in 2005, the migraine market is entering a state of maturity driven by the dominance of the triptan class of drugs. The ongoing approval delays with GlaxoSmithKline and Pozen's Trexima, coupled with triptan genericization, will result in the migraine market value decreasing by 20% from 2008 to $3.2 billion in 2015.

Published By Datamonitor
29 Mar 2007
ResearchWire
ResearchWire

Migraines: sales of triptans to double by 2007

Published By Datamonitor
12 Mar 2001

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.